Aspira Pathlab & Diagnostics Limited
Registered. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086
Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086
CIN: L85100MH1973PLC289209

Date: November 06, 2026

To,
Listing Department
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001.

Security Code: 540788
Security ID: ASPIRA

Sub: Outcome of Board Meeting held on Friday, November 06, 2026

Dear Sir/Madam,

In compliance with the SEBI (LODR) Regulations, 2015 ("Listing Regulations") this is to inform you that the Board of Directors of the Company, at its Meeting held today, i.e. on Friday, November 06, 2026 inter alia, has considered, approved and taken on record the following matter(s):

1. The Un-Audited Standalone Financial Results along with Auditor's Limited Review thereon for the Second Quarter and half yearly ended 30th September 2026.

In respect of the above, we hereby enclose the following:

i. The Un-Audited Standalone Financial results for the Second Quarter and half yearly ended 30th September 2026, in the format specified under Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and

ii. Limited Review Report issued by the Statutory Auditor of the Company on the Un-Audited Standalone Financial results for the Second Quarter and half yearly ended 30th September 2026.

Kindly note that Board Meeting commenced at 01.30 P.M (IST) and concluded at 04.00 P.M.(IST)

The above information is being made available on the website of the Company www.aspiradiagnostics.com.

We request you to kindly take the same on your record.

Thanking you.

Yours Faithfully,

For and on behalf of
Aspira Pathlab & Diagnostics Limited

Nikunj Velji Mange

Digitally signed by Nikunj Velji Mange
Date: 2026.11.06 16:12:14 +05'30'

Nikunj Mange
Manging Director
DIN: 08489442

Aspira Pathlab & Diagnostics Limited
Registered. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086
Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086
CIN: L85100MH1973PLC289209

CERTIFIED TRUE COPY OF THE RESOLUTION PASSED BY THE BOARD OF DIRECTORS OF ASPIRA PATHLAB & DIAGNOSTICS LIMITED ("THE COMPANY") IN ITS MEETING HELD ON FRIDAY, NOVEMBER 06, 2026 COMMENCED AT 01.30 P.M (IST) AT UNIT 6 & 7, GROUND FLOOR, BHAVESHWAR ARCADE PREMISES CO-OP. SOCIETY LTD, NITYANAND NAGAR, GHATKOPAR WEST, MUMBAI-400086, MAHARASHTRA

AUTHORISATION FOR SIGNING OF THE UNADUITED STANDALONE FINANCIAL RESULTS FOR THE SECOND QUARTER/HALF YEAR ENDED SEPTEMBER 30, 2026

"**RESOLVED THAT** pursuant to regulation 33(2)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the unaudited standalone financial results for the second quarter/half year ended September 30,2026 be and are hereby approved.

RESOLVED FURTHER THAT pursuant to regulation 33(2)(b) of the SEBI (LODR) Regulations, 2015, Mr. Nikunj Mange, Manging Director (DIN: 08489442) of the Company be and is hereby authorised on behalf of the Board members to sign the aforesaid unaudited standalone financial results for the second quarter/half year ended September 30,2026".

For and on behalf of
Aspira Pathlab & Diagnostics Limited

Nikunj Velji Mange
Digitally signed by Nikunj Velji Mange
Date: 2026.11.06 16:12:51 +05'30'

Nikunj Mange
Manging Director
DIN: 08489442

Sarda Soni Associates LLP

CHARTERED ACCOUNTANTS

Manoj Jain

B.Com(H), FCA, ACS, IP(ICAI), RV(S&FA)

Limited Review Report on unaudited financial results of Aspira Pathlab and Diagnostics Limited for the quarter and half year ended 30TH September, 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Aspira Pathlab & Diagnostics Limited

We have reviewed the accompanying statement of **Unaudited Financial Results** of **Aspira Pathlab & Diagnostics Limited** (hereinafter referred to as "the Company") for the quarter and half year ended 30TH September, 2026 ("the Statement"), being submitted by the company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations") including relevant circulars issued by SEBI from time to time.

This Statement, which is the responsibility of the company's management and approved by the company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of the company's personnel and analytical procedures applied to financial data and thus provide less assurance than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the SEBI under Regulation **33** (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended, to the extent applicable.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the accounting principles laid down in Ind AS 34 prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI LODR Regulations 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

SARDA SONI ASSOCIATES LLP * CHARTERED ACCOUNTANTS * FIRM REGN. NO. 117235 MUMBAI

11, Friend's Union Premises Co-operative Society Ltd., 2nd Floor, 227, P. D'Mello Road, Mumbai 400 001.
Phone: 022-2269 5289 ; Mobile: 98191 65816
Email: ssaaudit2102@gmail.com / sardasoniassociates2102@gmail.com
Nagpur (HO): "Chartered Square", Samrat Ashok Square, Saraipeth, Nagpur 400 009.
Phone: 0712-2726795, 2729471

Sarda Soni Associates LLP

CHARTERED ACCOUNTANTS

Manoj Jain

B.Com(H), FCA, ACS, IP(ICAI), RV(S&FA)

Emphasis of Matter

We draw attention to Note 5 to the Statement, which describes three summary suits filed against the Company aggregating to ₹111.50 lakh, plus interest and costs, the related proceedings before the Hon'ble Bombay High Court, and the demand drafts of ₹42.79 lakh included under Other Financial Assets at 30 September 2026. The outcome of these matters is presently uncertain, and no provision has been made in the Statement. The Claim continues to be disclosed as a contingent liability.

Our conclusion is not modified in respect of this matter.



For **SARDA SONI ASSOCIATES LLP**
Chartered Accountants
Firm Reg. No. 117235W

(MANOJ KUMAR JAIN)
Partner
Membership No.- 120788
UDIN : **26120788EUNDGB2178**

Place- Mumbai
Date- 06.11.2026

11, Friend's Union Premises Co-operative Society Ltd., 2nd Floor, 227, P. D'Mello Road, Mumbai 400 001.
Phone: 022-2269 5289 ; Mobile: 98191 65816
Email: ssaaudit2102@gmail.com / sardasoniassociates2102@gmail.com
Nagpur (HO): "Chartered Square", Samrat Ashok Square, Saraipeth, Nagpur 400 009.
Phone: 0712-2726795, 2729471

ASPIRA PATHLAB & DIAGNOSTICS LIMITED

(CIN L85100MH1973PLC289209)

Reg. Office : Flat No. 2, R.D. Shah Bldg., Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai -400086
Tel No. 022-71975756, Email :support@aspiradiagnostics.com,Website : www.aspiradiagnostics.com

Statement of Financial Results for the Quarter and Six months ended 30th September, 2026

(Rupees in Lakhs)

Particulars	Quarter ended			Six Months ended		Year ended
	30-Sep-26 (Unaudited)	30-Jun-26 (Unaudited)	30-Sep-25 (Unaudited)	30-Sep-26 (Unaudited)	30-Sep-25 (Unaudited)	31-Mar-26 (Audited)
1. Income						
(a) Revenue from Operations	626.04	616.91	809.28	1,242.94	1,334.08	2,498.20
(b) Other Income	8.51	11.95	13.96	20.45	24.73	51.59
Total income	**634.55**	**628.85**	**823.23**	**1,263.40**	**1,358.80**	**2,549.79**
2. Expenses						
(a) Cost of Materials consumed	133.44	87.75	128.27	221.19	217.87	452.04
(b) Laboratory Testing Charges	36.92	36.25	33.53	73.17	60.95	133.56
(c) Employee benefits expense	298.22	249.39	214.63	547.60	403.64	877.68
(d) Finance Costs	11.33	9.19	9.76	20.52	19.17	38.94
(e)Depreciation and amortisation expense	45.65	40.91	39.55	86.56	76.08	153.84
(f)Other expenses	224.94	209.13	213.94	434.07	350.62	888.60
Total Expenses	**750.50**	**632.62**	**639.69**	**1,383.12**	**1,128.32**	**2,544.67**
3. Profit / (Loss) before exceptional items and tax (1-2)	**(115.95)**	**(3.77)**	**183.54**	**(119.72)**	**230.49**	**5.13**
4. Exceptional Items	-	-	-	-	-	-
5. Profit / (Loss) before tax (3+4)	**(115.95)**	**(3.77)**	**183.54**	**(119.72)**	**230.49**	**5.13**
6. Tax Expenses	-	-	-	-	-	-
7. Profit / (Loss) after tax (5-6)	**(115.95)**	**(3.77)**	**183.54**	**(119.72)**	**230.49**	**5.13**
8. Other Comprehensive income(net of tax)	-	-	-	-	-	6.12
9. Total Comprehensive income/ (Loss) (7+8)	**(115.95)**	**(3.77)**	**183.54**	**(119.72)**	**230.49**	**11.25**
10. Paid up Equity share capital (face value of Rs.10 each)	1,029.30	1,029.30	1,029.30	1,029.30	1,029.30	1,029.30
11. Other Equity	-			-	-	193.80
12. Earning per share (in Rupees)						
(a) Basic	(1.13)	(0.04)	1.78	(1.16)	2.24	0.05
(b) Diluted	(1.13)	(0.04)	1.78	(1.16)	2.24	0.05

Notes

1. The above financial results of the Company for the quarter and six months ended September 30, 2026 have been reviewed and recommended by the Audit Committee and thereafter approved by the Board of Directors at its meeting held on 6th November, 2026.

2. The financial results for the quarter and six month ended September 30, 2026 has been subjected to limited review by statuatory auditors of the Company and not subjected to audit. The auditors have expressed an unmodified opinion in the limited review report for the quarter and six months ended September 30, 2026.

3. These financial results of the Company have been prepared in accordance with Indian Accounting standards (Ind AS) prescribed under Section 133 of the Companies Act 2013 read with Companies (Indian Accounting Standard) Rules, 2015, and in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and other accounting principles generally accepted in India, to the extent applicable.

4.Disclosure of segment wise information is not applicable, as pathology services is the Company's only business segment.

5. As disclosed in Note 35 to the financial statements for the year ended 31 March 2026, three lessors have filed three summary suits against the Company at Bhiwandi, claiming ₹111.50 lakh in aggregate for premature termination of leave-and-licence arrangements, plus interest at 12% p.a. and costs. On 6 May 2026, the Trial Court rejected the Company's applications for leave to defend. On the Company's writ petitions, which are pending, the Hon'ble Bombay High Court granted ad-interim relief subject to deposit of 50% of the claim (₹55.75 lakh), with time extended to early October 2026.

Demand drafts of ₹42.79 lakh, tendered but not accepted by the Trial Court owing to a shortfall, were held at 30 September 2026 and are included under Other Current Financial Assets. On 5 October 2026, the Company re-tendered them with further drafts of ₹12.96 lakh, without admitting liability.

Based on management's assessment, the outcome of these cases remains uncertain and no liability has presently crystallised. Management does not currently consider a payment more likely than not, and has therefore made no provision in these results. The claim continues to be disclosed as a contingent liability.

6. The previous period figures have been regrouped/rearrange/reclassified wherever necessary.

FOR **ASPIRA PATHLAB & DIAGNOSTICS LIMITED**

Nikunj Mange
Managing Director
DIN. 08489442
Place : Mumbai
Date : 6.11.2026

Aspira Pathlab & Diagnostics Limited Mumbai

FOR SARDA SONI ASSOCIATES LLP
CHARTERED ACCOUNTANTS

FIRM REGN. NO.117235 MUMBAI

(MANOJ KUMAR JAIN)
PARTNER
M. No.120788

Cash flow Statement for the period ended 30th Sep 2026

(All amounts in Lakhs, unless otherwise stated)

Particulars	For the period ended 30.09.2026 (₹) (Unaudited)	For the period ended 30.09.2025 (₹) (Unaudited)
A CASH FLOW FROM OPERATING ACTIVITIES		
Profit/(Loss) for the year	(119.72)	230.49
Adjustments for:		
Interest income	(20.45)	(24.73)
Bad debts	-	
Finance Costs	20.52	19.17
Depreciation and amortisation expenses	86.56	76.08
Profit on lease termination	-	1.30
Provision for impairment of trade receivables and advances	3.60	(13.11)
Operating profit before working capital changes	**(29.50)**	**289.19**
Working capital adjustments:		
(Increase)/Decrease in Trade receivables	(95.67)	(124.26)
(Increase)/Decrease in Inventories	(18.10)	(17.12)
(Increase)/Decrease in other Non Current advances	(53.64)	(15.88)
(Increase)/Decrease in Current Assets, Loans & advances and Other non-current assets	214.16	(139.71)
(Increase)/Decrease in other Current Assets	(7.51)	(15.65)
Increase/(Decrease) in Trade payables	43.41	21.51
Increase/(Decrease) in Provisions	6.55	8.06
Increase/(Decrease) in other Current and non current Liabilities	(1.07)	(6.01)
Increase/(Decrease) in Other financial liabilities	22.14	15.55
CASH GENERATED FROM OPERATIONS	**80.78**	**15.69**
Taxes Paid (net of refunds)	-	-
NET CASH (USED IN)/ GENERATED FROM OPERATING ACTIVITIES(A)	**80.78**	**15.69**
B CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property , plant and equipment	(68.73)	(18.69)
Purchase of Intangible assets	(16.50)	-
Net cash outflow on acquisition	-	(6.86)
(Increase)/Decrease in Investments	-	13.00
Advances given to parties	-	-
Proceeds from sale of fixed assets	-	-
Interest Received	20.45	24.73
NET CASH FLOW (USED IN)/ GENERATED FROM INVESTING ACTIVITIES - (B)	**(64.78)**	**12.18**
C CASH FLOWS FROM FINANCING ACTIVITIES		
Repayment of long term borrowings	8.11	7.24
Repayment of short term borrowings	-	-
Principal payment of Lease Liability	(53.75)	(42.20)
Interest paid on lease liabilities	(8.98)	(9.16)
Interest paid	(11.54)	(10.01)
Premium on issue of Shares	-	-
Proceeds from issue of shares	-	-
NET CASH (USED IN)/ GENERATED FROM FINANCING ACTIVITIES (C)	**(66.17)**	**(54.13)**
Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	(50.17)	(26.26)
Add:Cash and Cash Equivalents at the beginning of the year	126.46	175.24
Less: Cash Credits at the beginning of the year	-	-
Adjusted cash & cash equivalents at the beginning of the year	126.46	175.24
Cash and Cash Equivalents at the end of the year	76.30	148.98
Components of cash and cash equivalents comprise:		
Cash in hand	11.56	11.33
Balances with banks:		
-In Current Accounts	64.71	137.39
-In Escrow Account	0.03	0.26
-In Cash Credit Accounts	-	-
-Deposits with maturity less than 3 months	-	-
Cash and Cash Equivalents in cash flow statement	76.30	148.98

Note:

1) Cash and Cash equivalents represents cash in hand and balances with banks and Overdraft Facilities.
2) The above standalone Cash Flow Statement has been prepared under the 'Indirect Method' as set out in the Accounting Standard (Ind AS) 7 Statement of Cash Flows.
3)The previous period figures have been regrouped/rearrange/reclassified wherever necessary.

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED

Nikunj Mange
Managing Director
DIN. 08489442
Place : Mumbai
Date : 6.11.2026

FOR SARDA SONI ASSOCIATES LLP
CHARTERED ACCOUNTANTS

(MANOJ KUMAR JAIN)
PARTNER
M. No.120788

ASPIRA PATHLAB & DIAGNOSTICS LIMITED

(CIN : L85100MH1973PLC289209)

Reg. Office : Flat No. 2, R.D. Shah Bldg., Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai -400086

Tel No. 022-71975756, Email :support@aspiradiagnostics.com,Website : www.aspiradiagnostics.com

Balance Sheet as at 30 September 2026

	Particulars	As at 30 September 2026 (un-audited)	As at 30 September 2025 (un-audited)
A	**ASSETS**		
	Non-current assets		
	Property, plant and equipment	236.84	198.37
	Right of Use Assets	300.46	164.97
	Goodwill	330.56	305.72
	Other Intangible assets	17.58	1.58
	Financial Assests		
	(i) Investments in assosiates	-	-
	(ii) Loans and advances	371.53	347.91
	(iii) Others	140.72	317.29
	Total non-current assets	**1,397.68**	**1,335.83**
	Current Assets		
	Inventories	87.82	66.27
	Financial Assests		
	(i) Trade Receivables	265.48	371.35
	(ii) Cash and Cash Equivalents	76.30	148.98
	(iii) Bank balances other than (ii) above	-	39.96
	(iv) Others financial assets	43.09	3.73
	Current tax assets (net)	35.31	32.54
	Other Current Assets	17.07	17.64
	Total Current Assets	525.08	680.47
	Total Assets	**1,922.76**	**2,016.30**
B	**EQUITY AND LIABILITIES**		
	EQUITY		
	Equity share Capital	1,029.30	1,029.30
	Other equity	74.08	413.04
	Total Equity	1,103.38	1,442.34
	LIABILITIES		
	Non-current liabilites		
	Financial liabilites		
	(i) Borrowings	143.23	127.88
	(ii) Lease liabilities	229.72	96.70
	(iii) Other Financial Liabilities	8.38	-
	Provisions	69.98	63.43
	Total non-current liabilities	451.30	288.01
	Current liabilities		
	Financial liabilities		
	(i) Borrowings	-	-
	(ii) Lease liabilities	80.16	87.76
	(iii) Trade paybles		
	Total outstanding dues of micro and small enterprises	6.42	-
	Total outstanding dues of creditors other than micro and small enterprises	151.02	102.41
	(iv) Other financial liabilities	102.45	77.01
	Other current liabilities	16.53	14.05
	Provisions	11.49	4.73
	Total current libilities	**368.09**	**285.96**
	Total Liablities	**819.39**	**573.97**
	Total Equity and Liabilities	**1,922.76**	**2,016.30**

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED

Nikunj Mange

Managing Director

DIN. 08489442

Place : Mumbai

Date : 6.11.2026

Aspira Pathlab & Diagnostics Limited Mumbai

SARDA SONI ASSOCIATES LLP FIRM REGN. NO 117935 MUMBAI CHARTERED ACCOUNTANTS

FOR SARDA SONI ASSOCIATES LLP
CHARTERED ACCOUNTANTS

(MANOJ KUMAR JAIN)
PARTNER
M. No.120788

Aspira Pathlab & Diagnostics Limited
Registered. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086
Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086
CIN: L85100MH1973PLC289209

Date: November 06, 2026

To,
Corporate Relations Department
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001.

Scrip Code: 540788
Security ID: ASPIRA

Subject: Integrated Filing (Financial) for the quarter and half year ended 30 September 2026

In terms of provisions of Regulation 10(1A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD2/CIR/P/2024/185 dated 31 December 2024, and BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated 2 January 2025; the Integrated Filing (Financial) for the quarter and half year ended 30 September 2026 is enclosed herewith.

Kindly take the same on records

For **ASPIRA PATHLAB & DIAGNOSTIC LIMITED**

Nikunj Velji Mange

Digitally signed by Nikunj Velji Mange
Date: 2026.11.06 16:13:45 +05'30'

Nikunj Mange
Managing Director
DIN: 08489442

Aspira Pathlab & Diagnostics Limited
Registered. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086
Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086
CIN: L85100MH1973PLC289209

A. Financial Result – Annexure A

B. Statement on deviation or variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement etc.: **Not Applicable**

C. Format for disclosing outstanding default on Loans and Debt Securities: **Not Applicable as we don't have any default on loans and debt securities outstanding as on September 30, 2026.**

Sr. No.	Particulars	in ₹ crore
1.	**Loans / revolving facilities like cash credit from banks / financial institutions**	
A	Total amount outstanding as on date	**0**
B	Of the total amount outstanding, amount of default as on date	**0**
2.	**Unlisted debt securities i.e. NCDs and NCRPS**	
A	Total amount outstanding as on date	**0**
B	Of the total amount outstanding, amount of default as on date	**0**
3.	**Total financial indebtedness of the listed entity including short term and long-term debt**	**0**

D. Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter): **Applicable for this Quarter**

Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr. No.	Details of the party (listed entity/subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction	
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance
1	Aspira Pathlab & Diagnostics Limited	AAACL3049G	Mrs. Deepali Arvind Bhanushali	AAIPB4242P	Relative of Promoter	Remuneration			Audit Committee granted omnibus approval			831600.00	123000.00	103000.00
2	Aspira Pathlab & Diagnostics Limited	AAACL3049G	Yashraj Biotechnology Limited	AAACY0982C	Promoter Group	Sale of goods or services			Audit Committee granted omnibus approval			1012119.00	875020.00	1017205.00
3	Aspira Pathlab & Diagnostics Limited	AAACL3049G	Orangutan Gaming Private Limited	AANCA6217H	Enterprise over which Key Managerial Personnel are able to exercise significant influence	Sale of goods or services			Audit Committee granted omnibus approval			0.00	14510.00	0.00
4	Aspira Pathlab & Diagnostics Limited	AAACL3049G	Dr. Snehal Shah	AAGPS4890Q	Relative of Managing Director & CEO	Any other transaction	Professional / Consultancy Fees		Audit Committee granted omnibus approval			1230000.00	184500.00	184500.00
5	Aspira Pathlab & Diagnostics Limited	AAACL3049G	Dr. Pankaj Shah	AAGPS4891R	Relative of Managing Director & CEO	Any other transaction	Rent Expenses		Audit Committee granted omnibus approval			900000.00	13500.00	13500.00
6	Aspira Pathlab & Diagnostics Limited	AAACL3049G	Smt. Shashibala J. Shah	AAGPS4888J	Relative of Managing Director & CEO	Any other transaction	Rent Expenses		Audit Committee granted omnibus approval			1927530.00	294030.00	294030.00
7	Aspira Pathlab & Diagnostics Limited	AAACL3049G	Chartered Finance Management Private Limited	AABCC9172D	Common Director	Sale of goods or services			Audit Committee granted omnibus approval			34600.00	54235.00	13940.00
8	Aspira Pathlab & Diagnostics Limited	AAACL3049G	Yashraj Research Foundation	AAATY1128B	Common Promoters/ Board Of Trustee	Sale of goods or services			Audit Committee granted omnibus approval			10551759.00	0.00	10551759.00

E. Statement on Impact of Audit Qualifications (for Audit Report with unmodified opinion) submitted along-with annual Audited Financial Results (Standalone) (applicable only for Annual Filing i.e., 4th quarter): **Not Applicable for this Quarter**